期刊文献+

子宫肌瘤发生原因与临床治疗研究 被引量:3

Study on Causes and Clinical Treatment of Hysteromyoma
下载PDF
导出
摘要 目的探讨子宫肌瘤的发生原因与临床治疗。方法对医院妇科2013年1月—2015年1月共收治的76例子宫肌瘤患者病例资料进行分析,对发病原因和治疗情况进行探讨。结果病因方面,遗传因素占3.9%;内分泌因素占96.1%;治疗方面,保守治疗占43.4%,手术治疗占56.6%。结论针对子宫肌瘤的病因,制定个体化、科学、有效的治疗方法,可有效减少患者痛苦,提高治疗效果。 Objective To investigate the cause and clinical treatment of hysteromyoma. Methods The data of 76 cases of patients with hysteromyoma admitted in the Departement of Gynecological of the hospital between January 2013 and January 2015 were analyzed, and the pathogenesis and treatment are discussed. Results In terms of etiology, genetic factors accounted for 3.9% and endocrine factors accounted for 96.1%; in terms of treatment, conservative treatment accounted for 43.4%, and operation treatment 56.6%. Conclusion For hysteromyoma, individual, Scientific and effective treatment can effectively reduce the pain of the patient and improve the therapeutic efficacy.
作者 李游 李长双
出处 《中外医疗》 2015年第18期45-46,共2页 China & Foreign Medical Treatment
关键词 子宫肌瘤 发生原因 治疗 Hysteromyoma Causes Treatment
  • 相关文献

参考文献8

二级参考文献59

共引文献67

同被引文献68

  • 1Volker NA, Hehenkamp WJ, Smit P, et a/.Economic evalu- ation of uterine artery embolization versus hysterctomy in the treatment of symptomatic uterine fibroids:results from the randomized EMMY trial [J].J Vasc Interven Radiol, 2006,19(7) : 1007-1016.
  • 2Markowski DN, Bartnitzke S, L ning T.MED 12 mutations in uterinefibroids-their relationship to cytogenetic sub- groups[J].Int J Cancer, 2012,131 (7) : 1528-1536.
  • 3Mkinen N, Vahteristo P, Btitzow R,et a/.Exomie landscape of MED12 mutation-negative and -positive uterine leiomy- oma[J].Int J Cancer, 2014,133(4) : 1008-1012.
  • 4Shaik NA, Lone WG, Khan IA.Deteetion of somatic muta- tions and germline polymorphismsin mitochondrial DNA of uterine fibroids patients [J].Genet Test Mol Biomarker, 2011,15(7/8) :537-541.
  • 5Sabry M,A1-Hendy A.Medieal treatment of uterine leiomy- oma[Jl.Reorod Sci, 2012,19(4) : 339-353.
  • 6Dorenberg E J, Hol PK, Jakobsen JA,et a/.Improved infarc- tionrates in fibroids after the introduction of contrast- enhanced ultrasound during uterine artery embolization[J]. Acta Radiologica, 2012,53 ( 1 ) : 34-38.
  • 7Drazancic A.Antenatal care in developed countries--what should be done?[J].J Perinat Med, 2001,29 (3) : 188-192.
  • 8Bozzini N,Rodrigues CJ,Petti DA,et a/. Effects of treat- ment with gonadotropin releasing hormone agonist on the uterine leiomyomata structure [J].Acta Obstet Gynecol Scand, 2003,82(4) : 330-334.
  • 9Scialli AR,Jestila KJ. Sustained benefits of leuprolide ac- etate with or without subsequent medroxyprogesterone ac- etate in the nonsurgical management of leiomyomata u- teri[J].Fertil Steril, 1995,64(2) : 313-320.
  • 10Machado RB,de Souza IM,Beltrame A,et al. The lev- onorgestrel-releasing intrauterine system:its effect on the number of hysterectomies performed in perimenopausal women with uterine fibroids[J].Gynecol Endocrinol,2013, 29(5) :492-495.

引证文献3

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部